Payment overview · 2025
General Payments
$394.54
32 reported records · 6 companies
Healthcare provider profile · identity verified
Nancy P Bierman Birner, MD
Allopathic & Osteopathic Physicians|Pediatrics · SAINT LOUIS, MO · NPI 1043214778
Verified facts
What the public records show
CMS Open Payments records show Nancy P Bierman Birner, MD received $394.54 in general payments during 2025 across 32 reported records.
PFIZER INC. accounted for 34.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Nurtec Odt, Qulipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 172 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Nurtec Odt by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $136.34 | 34.6% | 18 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $79.63 | 20.2% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $69.97 | 17.7% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $61.22 | 15.5% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $31.01 | 7.9% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $16.37 | 4.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $394.54 | 32 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $136.34 | 18 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $113.19 | 17 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $79.63 | 3 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $69.97 | 4 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $31.55 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $31.01 | 2 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $23.15 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $16.37 | 1 | 2025 |
Source payment records
|
|||||
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $16.37 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $16.37 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $16.11 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $13.87 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $13.56 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 75 | exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
82 | 23 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
75 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
75 | 27 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
172 | 37 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 701 | 197 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 637 | 186 |
| Levothyroxine Sodium | Levothyroxine Sodium | 532 | 142 |
| Lisinopril | Lisinopril | 475 | 145 |
| Amlodipine Besylate | Amlodipine Besylate | 370 | 113 |
| Losartan Potassium | Losartan Potassium | 300 | 84 |
| Omeprazole | Omeprazole | 292 | 95 |
| Metformin Hcl | Metformin Hcl | 269 | 78 |
| Metoprolol Succinate | Metoprolol Succinate | 259 | 82 |
| Hydrochlorothiazide | Hydrochlorothiazide | 220 | 65 |
| Ezetimibe | Ezetimibe | 214 | 73 |
| Gabapentin | Gabapentin | 200 | 75 |
| Alendronate Sodium | Alendronate Sodium | 192 | 56 |
| Tramadol Hcl | Tramadol Hcl | 190 | 62 |
| Pantoprazole Sodium | Pantoprazole Sodium | 186 | 51 |
| Alprazolam | Alprazolam | 184 | 64 |
| Eliquis | Apixaban | 172 | 37 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 169 | 42 |
| Furosemide | Furosemide | 160 | 56 |
| Meloxicam | Meloxicam | 157 | 59 |
| Trazodone Hcl | Trazodone Hcl | 151 | 50 |
| Sertraline Hcl | Sertraline Hcl | 148 | 41 |
| Montelukast Sodium | Montelukast Sodium | 136 | 50 |
| Duloxetine Hcl | Duloxetine Hcl | 132 | 37 |
| Metoprolol Tartrate | Metoprolol Tartrate | 131 | 38 |
| Potassium Chloride | Potassium Chloride | 121 | 36 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 118 | 34 |
| Escitalopram Oxalate | Escitalopram Oxalate | 109 | 36 |
| Metformin Hcl Er | Metformin Hcl | 106 | 37 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 106 | 35 |
| Allopurinol | Allopurinol | 96 | 29 |
| Fluticasone Propionate | Fluticasone Propionate | 96 | 45 |
| Buspirone Hcl | Buspirone Hcl | 95 | 25 |
| Bupropion Xl | Bupropion Hcl | 94 | 27 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 91 | 46 |
| Pravastatin Sodium | Pravastatin Sodium | 90 | 28 |
| Atenolol | Atenolol | 89 | 25 |
| Tamsulosin Hcl | Tamsulosin Hcl | 87 | 28 |
| Jardiance | Empagliflozin | 82 | 23 |
| Carvedilol | Carvedilol | 80 | 27 |
| Famotidine | Famotidine | 79 | 32 |
| Lorazepam | Lorazepam | 78 | 30 |
| Clonazepam | Clonazepam | 75 | 19 |
| Mounjaro | Tirzepatide | 75 | 16 |
| Ozempic | Semaglutide | 75 | 27 |
| Mirtazapine | Mirtazapine | 71 | 25 |
| Simvastatin | Simvastatin | 71 | 22 |
| Clopidogrel | Clopidogrel Bisulfate | 69 | 22 |
| Spironolactone | Spironolactone | 69 | 23 |
| Citalopram Hbr | Citalopram Hydrobromide | 65 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 62 | 18 |
| Donepezil Hcl | Donepezil Hcl | 60 | 14 |
| Glipizide | Glipizide | 60 | 16 |
| Hydralazine Hcl | Hydralazine Hcl | 60 | 14 |
| Prednisone | Prednisone | 60 | 55 |
| Zolpidem Tartrate | Zolpidem Tartrate | 59 | 19 |
| Januvia | Sitagliptin Phosphate | 56 | 15 |
| Memantine Hcl | Memantine Hcl | 56 | 13 |
| Amoxicillin | Amoxicillin | 53 | 46 |
| Oxycodone Hcl | Oxycodone Hcl | 53 | 12 |
| Fenofibrate | Fenofibrate Nanocrystallized | 52 | 14 |
| Glimepiride | Glimepiride | 52 | 17 |
| Warfarin Sodium | Warfarin Sodium | 51 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 48 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 47 | 15 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 44 | 36 |
| Fenofibrate | Fenofibrate | 43 | 15 |
| Xarelto | Rivaroxaban | 43 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 40 | 36 |
| Glipizide Er | Glipizide | 40 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 40 | 14 |
| Pioglitazone Hcl | Pioglitazone Hcl | 40 | 14 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 39 | 24 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 38 | suppressed |
| Lovastatin | Lovastatin | 38 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 37 | 14 |
| Finasteride | Finasteride | 37 | 15 |
| Diclofenac Sodium | Diclofenac Sodium | 36 | 16 |
| Torsemide | Torsemide | 36 | 14 |
| Enalapril Maleate | Enalapril Maleate | 35 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 35 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 34 | suppressed |
| Synthroid | Levothyroxine Sodium | 33 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 31 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Diazepam | Diazepam | 29 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 29 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 29 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 28 | suppressed |
| Irbesartan | Irbesartan | 27 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 27 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 26 | suppressed |
| Levetiracetam | Levetiracetam | 26 | suppressed |
| Nifedipine Er | Nifedipine | 26 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 26 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 25 | 11 |
| Nebivolol Hcl | Nebivolol Hcl | 25 | suppressed |
| Celecoxib | Celecoxib | 24 | suppressed |
| Baclofen | Baclofen | 23 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 23 | suppressed |
| Repatha Sureclick | Evolocumab | 23 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 23 | 12 |
| Sildenafil Citrate | Sildenafil Citrate | 23 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 22 | suppressed |
| Ramipril | Ramipril | 22 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 22 | 15 |
| Estradiol | Estradiol | 21 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 21 | suppressed |
| Temazepam | Temazepam | 21 | suppressed |
| Chlorthalidone | Chlorthalidone | 20 | suppressed |
| Cephalexin | Cephalexin | 19 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 19 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 19 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 18 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 18 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 18 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 18 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 17 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 17 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 17 | suppressed |
| Sucralfate | Sucralfate | 17 | suppressed |
| Topiramate | Topiramate | 17 | suppressed |
| Vascepa | Icosapent Ethyl | 17 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 17 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 16 | 14 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 16 | suppressed |
| Myrbetriq | Mirabegron | 16 | suppressed |
| Primidone | Primidone | 16 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 16 | suppressed |
| Folic Acid | Folic Acid | 15 | suppressed |
| Nystatin | Nystatin | 15 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 15 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 15 | suppressed |
| Azithromycin | Azithromycin | 14 | 14 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 14 | suppressed |
| Lansoprazole | Lansoprazole | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Testosterone | Testosterone | 14 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 14 | suppressed |
| Carvedilol Er | Carvedilol Phosphate | 13 | suppressed |
| Fentanyl | Fentanyl | 13 | suppressed |
| Linzess | Linaclotide | 13 | suppressed |
| Methocarbamol | Methocarbamol | 13 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Trulicity | Dulaglutide | 13 | suppressed |
| Aripiprazole | Aripiprazole | 12 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Cilostazol | Cilostazol | 12 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 12 | 12 |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Loperamide | Loperamide Hcl | 12 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 12 | suppressed |
| Methimazole | Methimazole | 12 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Carisoprodol | Carisoprodol | 11 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 11 | suppressed |
| Dutasteride | Dutasteride | 11 | suppressed |
| Lagevrio (Eua) | Molnupiravir | 11 | 11 |
| Nortriptyline Hcl | Nortriptyline Hcl | 11 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 11 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 11 | suppressed |
| Pregabalin | Pregabalin | 11 | suppressed |
| Qulipta | Atogepant | 11 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $394.54 · 32 records | PFIZER INC. | AREXVY, BEXSERO, KISUNLA, MOUNJARO, NURTEC ODT, PAXLOVID, QULIPTA, SHINGRIX, The Cologuard Plus Collection Kit, UBRELVY, Wegovy, ZAVZPRET, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error